Skip to content
lifestyle.trondstidkontroll.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alvotech
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
November 11, 2026
Alvotech to Present at Upcoming Investor Conferences in November
November 2, 2026
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
October 28, 2026
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
October 20, 2026
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
October 14, 2026
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
October 6, 2026
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
October 5, 2026
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
August 31, 2026
Alvotech to present at upcoming investor conferences in September
August 27, 2026
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
August 21, 2026
1
2
3
Next Page
→